The purpose of this study is to investigate the safety and effectiveness of eltrombopag in treating children and adolescents with newly
diagnosed immune thrombocytopenia (ITP). Patients aged between 1 to <18 years with newly diagnosed ITP will be eligible to enroll if they consent to participate within ten days from diagnosis and have not received any prior therapy or if they have failed standard management and are within the
first three months from diagnosis. If you choose to participate, you will be on study for about 1 year. You will be randomly assigned to receive the
study drug eltrombopag or standard therapy. Participation in this study includes weekly procedures such as assessments, physical exams, review of
medical records, blood draws and questionnaires for 12 weeks and then about monthly or less often for up to 1 year.